Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Files An 8-K Financial Statements and ExhibitsItem 9.01.
AQUINOX PHARMACEUTICALS, INC ExhibitEX-99.1 2 d532727dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Aquinox Pharmaceuticals Announces Initiation of ProShip Phase 2 Proof-of-Concept Clinical Trial Investigating Rosiptor in CP/CPPS -Trial Will Enroll Approximately 100 Male Subjects in the US and Canada- VANCOUVER,…To view the full exhibit click
About Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology. Its primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells. The Company’s product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. It has completed and reported results from its Leadership trial, which is a multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial.